Compugen Ltd. (NASDAQ:CGEN) stock declared change of 384.25% away from 52-week low price and recently located move of -13.59% off 52-week high price. It has market worth of $1.18B . CGEN stock has been recorded 30.59% away from 50 day moving average and 104.45% away from 200 day moving average. Moving closer, we can see that shares have been trading 2.57% off 20-day moving average.

On May 06, 2020, Compugen Ltd. (NASDAQ:CGEN) a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, released financial results for the first quarter ended March 31, 2020.

We have entered 2020 well positioned and with significant momentum to advance our clinical programs that address novel, internally-discovered, drug targets for cancer immunotherapy, said Anat Cohen-Dayag, Ph.D., President and CEO of Compugen. On the clinical front, we recently presented at AACR updated data from our ongoing Phase 1 dose escalation study of COM701 as a monotherapy and in combination with Opdivo®. These encouraging data, which include signals of durable disease control and confirmed partial responses both in the monotherapy and combination arms, further confirm our hypothesis that by blocking PVRIG, an important new checkpoint, COM701 has the potential to broaden the patient population that can benefit from cancer immunotherapy. We also dosed the first patient in the Phase 1 study for COM902, our anti-TIGIT therapeutic antibody, which would enable us to clinically evaluate the dual blockade of PVRIG and TIGIT inhibitory pathways in the DNAM axis.

Dr. Cohen-Dayag added, Our continued progress and execution enabled us to successfully raise approximately $79 million through an underwritten public offering, which we believe is testament to the growing recognition of our science-driven approach backed by our computational discovery capabilities. With our strengthened balance sheet, we are well positioned to continue our strategic clinical development plans which will be expanded to also include a third clinical trial, a Phase 1/2 triple combination study testing COM701 with Bristol-Myers Squibb’s Opdivo® and their investigational TIGIT inhibitor in the second half of this year, as well as advance our early-stage programs to propel our future therapeutic pipeline. We are fortunate that, to date, the COVID-19 pandemic has not significantly impacted our operations, including our clinical development timelines. For now, we are not changing the anticipated data readouts and milestones timelines we previously provided. We are grateful to our employees and clinical investigators for their continued hard work and dedication. In these unique circumstances we remain focused on advancing our clinical and early-stage programs to maintain positive momentum to achieve our goals.

The Healthcare sector company, Compugen Ltd. noticed change of -10.13% to $13.22 along volume of 1367619 shares in recent session compared to an average volume of 1.17M. The stock observed return of 6.44% in 5 days trading activity. The stock was at 97.45% over one month performance. CGEN’s shares are at 85.97% for the quarter and driving a 314.37% return over the course of the past year and is now at 146.81% since this point in 2018.

The average volatility for the week at 6.53% and for month was at 8.35%. There are 80.26M shares outstanding and 76.12M shares are floated in market. Right now the stock beta is 2.86.